ReviewSmall science2025
MXene-Integrated Composites for Biomedical Applications: Synthesis, Cancer Diagnosis, and Emerging Frontiers.
Review in Small science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Advances in ultrasound-activated nano-sonosensitizers for cancer treatment: a systematic review and meta-analysis.Ultrasonics sonochemistry · 2026Pooled it
- Review
- Chelation Drives Surface Substitution in Hybrid-MXenes.Angewandte Chemie (International ed. in English) · 2026Article
- Double-Transition-Metal MXenes: Multimetallic 2D Platforms for Next-Generation Biomedicine.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- MXene-Protein Corona Interfaces for Molecular Profiling of Alzheimer's Disease.bioRxiv : the preprint server for biology · 2026Article
- NbAdvanced healthcare materials · 2026Article
- Recent Advances in Metal Phthalocyanine for Sensing Applications.Nanomaterials (Basel, Switzerland) · 2026Review
- Bright Photoluminescent Gd-MXene Quantum Dots for Cell Imaging with Synergistic MRI/CT Capability.Journal of fluorescence · 2026Article
- MXene-based electrochemical sensors for cancer biomarker detection: current trends, challenges, and future directions.Mikrochimica acta · 2025Review
- Advances in MXene Materials: Fabrication, Properties, and Applications.Materials (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MXenes, a novel class of two-dimensional (2D) transition metal carbides, carbonitrides, and nitrides, have gained significant attention in biomedicine. They are synthesized via two main approaches: top-down etching of MAX (here, M represents an early transition metal, A represents an element belonging to the A-group, and X represents N or C) phase precursors and bottom-up chemical reduction of metal oxides. While the MAX phase method requires high temperatures, influencing morphology and posing safety concerns, alternative non-MAX synthesis routes are emerging. Due to their unique physical and chemical properties, MXene-based composites hold great promise in regenerative medicine, biosensing, and cancer therapy. However, challenges related to their stability, controlled drug release, and biodegradability remain. This review explores advancements in MXene synthesis, emphasizing non-MAX phase fabrication and biomedical applications. Notably, MXene-based composites have shown remarkable potential in cancer treatment, particularly in photothermal and photodynamic therapy. Their mechanisms, advantages, and limitations are discussed, along with future prospects and challenges in clinical translation. The development of MXene composites offers new avenues for innovative cancer therapies, paving the way for improved treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.